These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16315791)

  • 1. Treatment of pulmonary hypertension secondary to alveolar microlithiasis with Bosentan: a case report.
    Gialafos EJ; Moyssakis I; Taktikou H; Voteas V; Sfikakis PP
    Sarcoidosis Vasc Diffuse Lung Dis; 2005 Oct; 22(3):237. PubMed ID: 16315791
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe pulmonary hypertension due to pulmonary alveolar microlithiasis.
    Synetos A; Dilaveris P; Gialafos E; Giannopoulos G; Stefanadis C
    Int J Cardiol; 2006 Jan; 106(3):396-7. PubMed ID: 16337051
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary alveolar microlithiasis: a rare cause of severe pulmonary hypertension.
    Yetkin O
    Int J Cardiol; 2007 May; 118(1):133-4; author reply 132. PubMed ID: 16938361
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan.
    Clift PF; Townend JN; Bramhall S; Isaac JL
    Transplantation; 2004 Jun; 77(11):1774-5. PubMed ID: 15201683
    [No Abstract]   [Full Text] [Related]  

  • 5. Portopulmonary hypertension associated with congenital absence of the portal vein treated with bosentan.
    Hino T; Hayashida A; Okahashi N; Wada N; Watanabe N; Obase K; Neishi Y; Kawamoto T; Okura H; Yoshida K
    Intern Med; 2009; 48(8):597-600. PubMed ID: 19367055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan treatment in an adult with pulmonary hypertension due to patent ductus arteriosus permits surgical repair.
    Mitropoulos FA; Apostolopoulou SC; Kanakis MA; Rammos S; Anagnostopoulos CE
    J Heart Lung Transplant; 2007 Dec; 26(12):1345-6. PubMed ID: 18096490
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of pulmonary arterial hypertension: a step forward.
    Sharma S
    Chest; 2003 Jul; 124(1):8-11. PubMed ID: 12853493
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan.
    Foley RJ; Metersky ML
    Respiration; 2008; 75(2):211-4. PubMed ID: 16293957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bosentán, hope or reality for the treatment of pulmonary arterial hypertension].
    Callejas Rubio JL; Ortego Centeno N; Benticuaga Martínez MN; de la Higuera Torres-Pujol JM
    Med Clin (Barc); 2004 Jun; 123(4):158-9, author reply 159. PubMed ID: 15274815
    [No Abstract]   [Full Text] [Related]  

  • 10. Ease symptoms of pulmonary hypertension with bosentan.
    Kupecz D; Berardinelli C
    Nurse Pract; 2002 Jun; 27(6):51-3. PubMed ID: 12094086
    [No Abstract]   [Full Text] [Related]  

  • 11. A new era in the treatment of primary pulmonary hypertension.
    Bailey CL; Channick RN; Rubin LJ
    Heart; 2001 Mar; 85(3):251-2. PubMed ID: 11179256
    [No Abstract]   [Full Text] [Related]  

  • 12. [Long-term therapy with endothelin-1 antagonist for pulmonary hypertension secondary to systemic sclerosis].
    Shalev L; Langevitz P; Zandman-Goddard G
    Harefuah; 2008 Apr; 147(4):287-9, 376. PubMed ID: 18686806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment.
    Dimitroulas T; Giannakoulas G; Karvounis H; Dimitroula H; Settas L
    Rheumatol Int; 2009 Jan; 29(3):347-8. PubMed ID: 18690444
    [No Abstract]   [Full Text] [Related]  

  • 14. Bosentan treatment for pulmonary arterial hypertension due to complete atrioventricular septal defect in an infant with Down's syndrome.
    Ren R; He F; Xiao X
    Int J Cardiol; 2014 Dec; 177(3):1054-5. PubMed ID: 25465836
    [No Abstract]   [Full Text] [Related]  

  • 15. Bosentan improves functional class, pulmonary artery systolic pressure, and DLCO in scleroderma patients with pulmonary hypertension: a possible synergy with iloprost.
    Beretta L; Scorza R; Del Papa N; Mazzone A
    J Rheumatol; 2006 Sep; 33(9):1915-6; author reply 1916. PubMed ID: 16960959
    [No Abstract]   [Full Text] [Related]  

  • 16. Bosentan in mild pulmonary hypertension.
    Giannakoulas G; Dimopoulos K; Gatzoulis MA
    Lancet; 2008 Nov; 372(9651):1730-1; author reply 1731. PubMed ID: 19013315
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension.
    Anthi A; Tsangaris I; Hamodraka ES; Lekakis J; Armaganidis A; Orfanos SE
    Blood; 2012 Aug; 120(7):1531-2. PubMed ID: 22899478
    [No Abstract]   [Full Text] [Related]  

  • 18. Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension.
    Hamaguchi Y; Fujimoto M; Hasegawa M; Matsushita T; Takehara K
    J Dermatol Sci; 2009 Jul; 55(1):66-7. PubMed ID: 19342201
    [No Abstract]   [Full Text] [Related]  

  • 19. Bosentan treatment for pulmonary arterial hypertension due to patent ductus arteriosus and Down's syndrome in an infant.
    He J; Ren Y; Chen Y; Feng Y
    Int J Cardiol; 2014 Oct; 176(3):e117-8. PubMed ID: 25129297
    [No Abstract]   [Full Text] [Related]  

  • 20. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.